KRAS and lung cancer: This biochemical logic was nicely underscored by Kauko et al. who showed that PP2A inhibition achieved by siRNA-mediated knockdown of Aα, conferred resistance to a MEK inhibitor in KRAS-mutant lung cancer cells (169).